In theory, with time, patients on C5-inhibiting therapy could convert their phenotype from aHUS to a C3-mediated glomerular disease (e.g., complement 3 glomerulopathy [C3G]; refs. 32, 33) as opposed to a C5/terminal pathway–mediated disease. This evidence concerns the gene C5 and complement 3 glomerulopathy.